Overview
I am a neuro-oncologist, neurologist, and palliative care physician at the Preston Robert Tisch Brain Tumor Center. I also provide neuro-oncology expertise for the National Tele-Oncology Program and National Precision Oncology Program at the Veteran's Health Administration. My clinical and research interests encompass supportive care and palliative care with a special interest in older adults with brain tumors. The incidence of malignant brain tumors like glioblastoma and non-malignant tumors like meningioma affect aging populations and it is crucial to be able to provide better care for these patients.
Current Appointments & Affiliations
Associate Professor of Neurosurgery
·
2025 - Present
Neurosurgery,
Neurosurgery
Associate Professor in Neurology
·
2025 - Present
Neurology, General & Community Neurology,
Neurology
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Associations Between Problem List Items and Clinically Significant Distress in Patients with Metastatic Spine Disease.
Journal Article Spine (Phila Pa 1976) · March 25, 2025 STUDY DESIGN: Retrospective cohort study. OBJECTIVE: This study aimed to identify sources of distress in patients with metastatic spine disease and elucidate factors associated with clinically significant distress. SUMMARY OF BACKGROUND DATA: Distress is a ... Full text Link to item CitePerioperative Trends in Distress Among Cancer Patients: A Systematic Review and Meta-Analysis.
Journal Article Cancer Med · March 2025 INTRODUCTION: Distress is common among cancer patients, especially those undergoing surgery. However, no study has systematically analyzed distress trends in this population. The purpose of this study was to systematically review perioperative rates of dis ... Full text Link to item CiteFinancial toxicity of oral chemotherapy in patients with primary brain tumors.
Journal Article Neuro-oncology practice · February 2025 BackgroundCancer treatment costs continue to rise with the development of new agents. Financial toxicity is defined as the quantifiable costs associated with cancer and cancer treatment in addition to the patient's associated distress. This study' ... Full text CiteRecent Grants
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Clinical TrialPrincipal Investigator · Awarded by Chimerix, Inc. · 2023 - 2028Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with NF2 Mutated Meningiomas
Clinical TrialPrincipal Investigator · Awarded by Recursion Pharmaceuticals, Inc · 2022 - 2027A Randomized Phase II Study of Nivolumab and Temozolomide vs Temozolomide alone in newly diagnosed elderly patients with Glioblastoma (NUTMEG)
Clinical TrialPrincipal Investigator · Awarded by University of Sydney · 2020 - 2022View All Grants
Education, Training & Certifications
Tulane University, School of Medicine ·
2011
M.D.
The George Washington University ·
2006
M.P.H.
Northwestern University ·
2001
B.A.